Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 14,331 Shares

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 14,331 shares of the stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $3.53, for a total transaction of $50,588.43. Following the completion of the transaction, the insider now owns 1,285,794 shares in the company, valued at $4,538,852.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The shares were sold at an average price of $3.50, for a total transaction of $28,224.00.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Stock Performance

Shares of GNLX opened at $3.45 on Thursday. The company’s 50 day simple moving average is $5.86 and its 200-day simple moving average is $10.95. Genelux Co. has a 12-month low of $3.26 and a 12-month high of $40.98.

Genelux (NASDAQ:GNLX) last announced its earnings results on Friday, March 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). As a group, analysts expect that Genelux Co. will post -0.81 earnings per share for the current year.

Hedge Funds Weigh In On Genelux

A number of hedge funds have recently modified their holdings of GNLX. Amalgamated Bank lifted its holdings in shares of Genelux by 250.8% during the third quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock worth $26,000 after purchasing an additional 770 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Genelux by 17.6% during the fourth quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock worth $91,000 after purchasing an additional 966 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of Genelux by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock worth $87,000 after purchasing an additional 1,573 shares during the period. Falcon Wealth Planning lifted its holdings in shares of Genelux by 20.0% during the fourth quarter. Falcon Wealth Planning now owns 12,000 shares of the company’s stock worth $168,000 after purchasing an additional 2,000 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Genelux by 216.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock worth $41,000 after purchasing an additional 2,021 shares during the period. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GNLX has been the topic of several recent analyst reports. HC Wainwright dropped their price target on shares of Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Benchmark restated a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a research report on Wednesday, April 3rd.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.